Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

1994 • 5,204 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Prognostic significance of morphologic parameters in renal cell carcinoma

1982 • 2,700 citations

Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma

1999 • 1,782 citations

Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer

2001 • 1,309 citations

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

1998 • 962 citations

Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells

2001 • 937 citations

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids

2000 • 652 citations

Involvement of LOX-1 in Dendritic Cell-Mediated Antigen Cross-Presentation

2002 • 524 citations

Dendritic cells as a tool to induce anergic and regulatory T cells

2001 • 478 citations

TNM staging of renal cell carcinoma

1997 • 463 citations

Human naive and memory T lymphocytes differ in telomeric length and replicative potential.

1995 • 424 citations

A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma

2002 • 340 citations

Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens

1999 • 239 citations

Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells.

2000 • 222 citations

Multicenter, Randomized, Phase III Trial of CD8⁺ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma

1999 • 212 citations

Interleukin-2 Based Home Therapy of Metastatic Renal Cell Carcinoma: Risks and Benefits in 215 Consecutive Single Institution Patients

1996 • 197 citations

Treatment of Metastatic Renal Cell Carcinoma With Nephrectomy, Interleukin-2 and Cytokine-Primed or CD8(+) Selected Tumor Infiltrating Lymphocytes from Primary Tumor

1997 • 162 citations

Human renal-cell carcinoma tissue contains dendritic cells

1996 • 152 citations

Characterization of a Human Renal Cell Carcinoma Specific Cytotoxic CD8+ T Cell Line

1992 • 100 citations

IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.

2001 • 85 citations

Interferon- α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon- α as Therapy for Metastatic Renal Cell Carcinoma

1993 • 75 citations

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

1999 • 71 citations

Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones

1994 • 64 citations

In situ demonstration of renal-cell-carcinoma-specific T-cell clones

1996 • 51 citations

High-Fold Expansion of Human Cytotoxic T-Lymphocytes Specific for Autologous Melanoma Cells for Use in Immunotherapy

1991 • 44 citations

Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line

1997 • 30 citations

Immunotherapy of metastatic renal cell cancer

1996 • 22 citations

Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.

2000 • 14 citations

Treatment of Advanced Renal Cell Carcinoma Using Regional Arterial Administration of Lymphokine-Activated Killer Cells in Combination with Low Doses of rlL-2

1994 • 13 citations

Deleted Work

1955 • 0 citations